Gallant ICD Solutions

Single and Dual chamber Implantable Cardioverter Defibrillators

Proven Therapy Assurance

Key clinical outcomes for Gallant™ ICD solutions include:

98.4% of patients did not receive inappropriate shocks in REDUCE-IT study (CI:97.2-99.2, p<0.0001)1

>800 patients annually with challenging arrhythmias could have their lives saved because of VF Therapy Assurance2

Manuals & Technical Resources

Manuals & Technical Resources

Reimbursement & Coding

Reimbursement & Coding

Customer Service

Customer Service

References

  1. Veltmann C, Wöhrle A, Busch M, et al. Reduction of inappropriate shocks of ICDs with enhanced SVT discriminators. EUROPACE presentation; 2017.
  2. Data on file. 60101422 Internal Validation Report. Total 2019 global high-voltage implants, all manufacturers, estimated to be 440,434 units (Source: Abbott Market Research).

MAT-2007477 v2.0